Loading...
•
Sep 30
Balchem Q3 2025 Earnings Report
Balchem reported its financial results for the third quarter of 2025, highlighting record net sales and adjusted EBITDA, alongside growth across all reporting segments.
Key Takeaways
Balchem delivered strong third-quarter results, driven by market penetration of specialty nutrients and delivery systems, and favorable trends in food and nutrition. The company achieved record net sales of $267.6 million and record adjusted EBITDA of $71.4 million, with growth in sales and earnings from operations across all three reporting segments.
Record net sales reached $267.6 million, marking a 5% increase compared to the prior year quarter.
GAAP net earnings were $40.3 million, a 1% increase from the prior year quarter.
Record adjusted EBITDA stood at $71.4 million, consistent with the prior year quarter.
GAAP EPS was $1.24, and adjusted EPS was a record $1.35, showing significant increases from the prior year.
Balchem
Balchem
Forward Guidance
Balchem is moving forward with a significant expansion project for its microencapsulation manufacturing facility, which is expected to more than double its capacity. The company also highlighted positive results from sponsored research efforts, including a key study on choline biomarkers.
Positive Outlook
- Received approvals for a new state-of-the-art food ingredient and nutraceutical microencapsulation manufacturing facility in Orange County, NY.
- The new facility will more than double capacity for fast-growing microencapsulation technologies.
- Good results year to date from sponsored research efforts, with five new studies published in Q3.
- Successful identification of choline and betaine concentrations as predictors of dietary choline intake in a key biomarker study.
- Strong cash flows enabled net repayments on revolving debt of $36.0 million, reducing net debt to $88.9 million.